Skip to content

Improving detection and prevention of cognitive decline in ageing

Assessment of age and disease related cognitive impairment in normal volunteers and people with degenerative and vascular brain disease and assessment of the potential neuroplastic effect of non pharmacological treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN42025084
Enrollment
500
Registered
2013-07-31
Start date
2013-02-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Dementias and Neurodegenerative Diseases Research Network

Interventions

Cognitive Stimulation, Face to Face interview and Psychometric tests, administered by experienced research neuropsychologists at Royal Hallamshire Hospital.

Sponsors

Sheffield Teaching Hospitals NHS Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Any volunteer with no history of neurological or psychiatric disorders, and fluent in English will be eligible for the study 2. Any patient who experiences cognitive change as a result of neurodegenerative disease, vascular brain disease or dementia due to other causes, and fluent in English may be included 3. Target Gender: Male & Female; Upper Age Limit 100 years ; Lower Age Limit 18 years

Exclusion criteria

Exclusion criteria: 1. Any volunteer with history of neurological or psychiatric disorders, substance abuse, persistent use of psychoactive drugs, history of traumatic brain injury with loss of consciousness, or non-fluent in English will not be eligible for inclusion 2. Patients with perceptual deficits or advanced dementia who are unable to complete assessments, or who are non-fluent in English, or patients who clearly lack capacity to give consent will not be eligible for inclusion

Design outcomes

Primary

MeasureTime frame
Resting state functional magnetic resonance imaging (fMRI); Timepoints: Baseline and at 6 month intervals

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026